Neurotechnology Industry Reports Revenues of $143.1 Billion in 2009
Boston, May 19, 2010 -- NeuroInsights, the neurotech market authority, announced the release of the sixth annual investment guide and market analysis of the global neurological disease and psychiatric illness markets. Unveiled during the annual Neurotech Investing and Partnering Conference in Boston, this 500-page report enables investors, companies and governments to assess opportunities, calculate risks and understand the dynamics of this continually changing market.
"The neurotechnology industry faced many challenges in 2009 which negatively impacted overall revenue growth," said Casey Lynch, Managing Director of NeuroInsights. "Nonetheless, commercial neuroscience represents the largest unmet medical market opportunity in healthcare. Investors recognize the opportunity, which is why nearly $1.6 billion was invested in private CNS drug, device and diagnostic companies last year.”
Specific findings from the Neurotechnology Industry 2010 Report show that in 2009:
- Venture capital investment in neurotechnology was up 9.5% to $1.58 billion
- More than 250 venture investors participated in neurotech financings in 2009
- Global neurotech industry revenues shrank 1.2% to $143.1 billion
- Neuropharmaceuticals recorded revenues of $121 billion with -0.7% annual growth
- Neurodevices recorded revenues of $7.1 billion with 15% annual growth
- Neurodiagnostics recorded revenues of $15 billion with -11% annual growth
- Brain-related illness is the largest unmet medical market: 2 billion people worldwide
Specific milestones from the report were presented during the 5th annual Neurotech Industry Investing and Partnering Conference, co-hosted by the Neurotechnology Industry Organization and NeuroInsights. This conference, held at the Westin Boston Waterfront today and tomorrow, is the premier global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.
“The record number of attendees at this meeting is a testament to the high level of investor interest and clinical progress being made across neurotechnology,” said Zack Lynch. “With over 2 billion people worldwide suffering from a neurological disease, psychiatric illness or nervous system injury, this continued momentum can not come fast enough.”
The Neurotechnology Industry 2010 Report: Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System tracks developments and helps guide strategic business development and investment decisions in neurotech. This year’s report provides an in-depth look at more than 16 brain and nervous system disorders and treatments in development at over 500 public and private companies, including: Alzheimer's disease, addiction, ADHD, anxiety, depression, epilepsy, migraine, mild cognitive impairment, multiple sclerosis, obesity, pain, Parkinson's disease, schizophrenia, retinal disorders, sleep disorders, stroke and traumatic brain injury. Corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry are fully assessed with detailed insights.
The Neurotechnology Industry 2010 Report: Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System is now available for purchase in hard copy or pdf format at http://www.neuroinsights.com/marketreports/marketreport2010.html
Neurotechnology Industry Organization